Antibodies as Drugs

 说明(由申请人提供)：请求支持由Peter D.Senter、Anna M.Wu、Alan J.Korman和Karl Dane Wittrup组织的题为抗体作为药物的Keystone研讨会。会议将于2016年3月6日至10日在加拿大不列颠哥伦比亚省惠斯勒举行。单抗已经在医学和生物学方面产生了显著的影响，大量已被批准的药物被用于癌症、免疫疾病和传染病的诊断、治疗和表征。由于其精致的靶点特异性，加上其良好的药理学特性，抗体注定会产生更大的临床影响，特别是在分子水平上理解的疾病。本次Keystone研讨会将集中关注基于抗体的技术的许多关键进展以及该领域的发展方向。一些关键问题将包括：1)抗体的结构和功能；2)改进疗效的工程抗体和抗体样分子；3)抗体的药理特性和生物分布；4)基于抗体的癌症和传染病的治疗；5)以共刺激通路和免疫检查点为靶点；6)抗体作为药物、细胞因子、放射性同位素和显像剂的载体；7)抗体模拟；8)临床进展和挑战。这次会议已经成为一个既定的论坛，吸引了来自全球学术界、工业界和研究机构的新的研究人员和该领域的领导人。会议的目标将是解决面临的关键问题 以抗体为基础的治疗学的广泛领域，提供了最新进展的概述，并将跨学科小组聚集在一起，以产生新的想法和有希望的研究领域。同时召开的癌症疫苗：针对免疫治疗的癌症基因会议将显著增加跨学科互动的机会，该会议将与本次会议共举行两次全体会议。本次会议的总议题与 NIAID代表团非常重视这次会议对治疗癌症和其他疾病的免疫机制的重视。

 DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled Antibodies as Drugs, organized by Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup. The meeting will be held in Whistler, British Columbia, Canada from March 6-10, 2016. Monoclonal antibodies have had a pronounced impact in medicine and biology, with a broad array of approved agents that are used for the diagnosis, treatment and characterization of cancers, immunological disorders, and infectious diseases. Because of their exquisite target specificities, together with their favorable pharmacologic properties, antibodies are destined to have even increased clinical impact, particularly in diseases that are understood at the molecular level. This Keystone Symposia meeting will focus attention on many of the key advances in antibody-based technologies as well as on where the field is heading. Some of the critical topics that will be include: 1) Antibody structure and function; 2) Engineered antibodies and antibody-like molecules for improved efficacy; 3) Antibody pharmacologic properties and biologic distribution; 4) Antibody-based therapies for cancer and infectious diseases; 5) Targeting co-stimulatory pathways and immunological checkpoints; 6) Antibodies as carriers of drugs, cytokines, radioisotopes and imaging agents; 7) Antibody mimetics; and 8) Clinical advancements and challenges. This meeting has become an established forum that attracts both new investigators and leaders in the field, coming from academia, industry and research institutes around the globe. The goals of the meeting will be to address the critical issues facing the broad field of antibody-based therapeutics, provide an overview of recent advances and bring together interdisciplinary groups for the generation of new ideas and promising areas of investigation. Opportunities for interdisciplinary interactions will be significantly enhanced by te concurrent meeting on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, which will share two plenary sessions with this meeting. The general topic of this meeting is relevant to the NIAID mission given the strong emphasis the meeting will have on immunological mechanisms for the treatment of cancer and other diseases.